Penpulimab in Maintenance Therapy in Lymphoma

Inclusion Criteria: 1. Lymphoma patients who received transplantation or were intolerant to transplantation achieved remission after previous induction and consolidation therapy. Patients who were intolerant to transplantation here referred to lymphoma patients ≥60 years old or \< 60 years old and recommended for transplantation by the guidelines; 2. Age ≥18 years old; 3. ECOG PS\< 2 points; 4. Life expectancy is more than 3 months; 5. Patients were allowed to receive radiotherapy, but the last radiotherapy was given more than 7 days before the initial study drug administration; 6. Normal liver and kidney function, specific for direct bilirubin in serum, serum indirect bilirubin and/or cereal third transaminase, aspertate aminotransferase, serum creatinine 2 or less normal limit, creatinine clearance or ≥60 mL/min. 7. Normal bone marrow function, specific defined as absolute neutrophil count (ANC) acuity ≥1.0\*10\^9 / L, platelet ≥50 \*10\^9/L and ≥70 g/L or higher hemoglobin; 8. Women of childbearing age who used contraception or had a negative pregnancy test before enrollment, and who used contraception during the test period and within 8 weeks of the last drug administration; For men who were methodically contracepted or surgically sterilized during the trial period and 8 weeks after the last dose; 9. The subjects voluntarily joined the study and signed the informed consent with good compliance and follow-up. Exclusion Criteria: * 1\. Pregnant or lactating women; 2\. Patients with a history of autoimmune diseases or syndromes requiring systemic use of steroid immunosuppressants, such as pituitaritis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism, hypothyroidism, etc.; 3\. The patient had received systemic glucocorticoids (prednisone \&gt; 20mg/ day) therapy (excluding nasal spray, inhaled or other topical corticosteroids) or any other form of immunosuppressive therapy; 4\. Uncontrolled heart disease, including unstable angina, acute myocardial infarction 6 months before randomization, congestive heart failure (NYHA) with a grade III or IV heart function; Or left ventricular ejection fraction \&lt; 50%; 5\. Known allergy to test drug ingredients; 6\. Patients receiving organ transplants; 7\. Has been diagnosed with or is undergoing treatment for a malignancy other than lymphoma, except for: * had received treatment for the purpose of cure, and had no malignancies with known active disease for ≥5 years prior to enrollment; * Well-treated basal cell carcinoma of the skin with no signs of disease (except melanoma); * Well-treated carcinoma in situ of the cervix with no signs of disease. 8\. Patients with grade 3 or above neurotoxic reactions in the two weeks prior to treatment; 9\. Severely infected persons; 10\. Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study or the evaluation of the study results; 11\. Those who were considered unsuitable for inclusion by the researchers.